April 28, 2020 / 12:22 PM / a month ago

BRIEF-Roche Canada Says Health Canada Approves Rozlytrek For Ntrk Gene Fusion-Positive Solid Tumours In Locally Advanced Or Metastatic Patients

April 28 (Reuters) - Roche Holding AG:

* ROCHE CANADA - HEALTH CANADA APPROVES ROZLYTREK (ENTRECTINIB) FOR NTRK GENE FUSION-POSITIVE SOLID TUMOURS IN LOCALLY ADVANCED OR METASTATIC PATIENTS

* ROCHE CANADA - ON FEB 10, 2020, HEALTH CANADA, UNDER NOTICE OF COMPLIANCE WITH CONDITIONS (NOC/C) POLICY, APPROVED ROZLYTREK (ENTRECTINIB) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below